abstract: BACKGROUND AND PURPOSE: There are limited data on the extent of blood-brain barrier (BBB) compromise in acute @entity1779 @entity1 . We tested the hypotheses that BBB compromise measured with permeability-surface area product ( @entity14554 ) is increased in the perihematoma region and predicts perihematoma @entity4 growth in acute @entity1779 @entity1 . METHODS: @entity1 were randomized within 24 hours of symptom onset to a systolic blood pressure (SBP) treatment of <150 (n=26) or <180 mm Hg (n=27). Permeability maps were generated using computed tomographic perfusion source data acquired 2 hours after randomization, and mean @entity14554 was measured in the @entity1410 , perihematoma, and hemispheric regions. @entity1410 and @entity4 volumes were measured on noncontrast computed tomographic scans obtained at baseline, 2 hours and 24 hours after randomization. RESULTS: @entity1 were randomized at a median (interquartile range) time of 9.3 hours (14.1) from symptom onset. Treatment groups were balanced with respect to baseline SBP and @entity1410 volume. Perihematoma @entity14554 (5.1  2.4 mL/100 mL per minute) was higher than @entity14554 in contralateral regions (3.6  1.7 mL/100 mL per minute; P<0.001). Relative @entity4 growth (0-24 hours) was not predicted by perihematoma @entity14554 (b=-0.192 [-0.06 to 0.01]) or SBP change (b=-0.092 [-0.002 to 0.001]). SBP was lower in the <150 target group (139.2  22.1 mm Hg) than in the <180 group (159.7  12.3 mm Hg; P<0.0001). Perihematoma @entity14554 was not different between groups (4.9  2.4 mL/100 mL per minute for the <150 group, 5.3  2.4 mL/100 mL per minute for the <180 group; P=0.51). CONCLUSIONS: BBB permeability is focally increased in the @entity1410 and perihematoma regions of acute @entity1779 @entity1 . BBB compromise does not predict acute perihematoma @entity4 volume or @entity4 growth. SBP reduction does not affect BBB permeability. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00963976.

title: Blood-Brain Barrier Compromise Does Not Predict XXXX Growth in @entity1779 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1410 :: ('MESH:D006406', 'Disease') :: ['Hematoma', 'hematoma']

entities_list: @entity1779 :: ('MESH:D002543', 'Disease') :: ['intracerebral hemorrhage']

answer: @entity4 :: (MESH:D004487,Disease) :: ['Perihematoma Edema']


abstract: BACKGROUND: Neoadjuvant therapies have significantly improved local control and survival of @entity1 with @entity5 . Nevertheless, although a complete pathologic response can be achieved in 30% of cases, a transabdominal surgical resection is always required. This study aimed, for the first time, to test in the literature the feasibility of local excision combined with transanal endoscopic microsurgery (TEM) as a surgical option for @entity1 treated with neoadjuvant chemoradiation. METHODS: Between July 1997 and December 2002, 30 @entity1 with @entity5 affected by an extraperitoneal @entity5 entered a protocol consisting of neoadjuvant chemoradiation followed by surgery. The surgical treatment, consisting of open surgery, local excision, or TEM, was planned according to the @entity1 's clinical response after chemoradiation and distance from the anal verge. RESULTS: A significant clinical downstaging was observed in eight @entity1 . Five of these @entity1 underwent TEM, and three had local excision. Consequently, open surgery was performed for 22 @entity1 . Histology showed six cases of complete pathologic response: three in the open surgery group and three in the transanal excision group. After a mean follow-up period of 47 months, the disease-free survival rate was 77% in the open surgery group and 100% in TEM or local excision group. CONCLUSIONS: The findings suggest the complementary feasibility of TEM and local excision after neoadjuvant chemoradiation. However, randomized trials are needed to confirm the oncologic safety of this approach.

title: Complementary use of local excision and transanal endoscopic microsurgery for XXXX after neoadjuvant chemoradiation.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'rectal cancer']

answer: @entity5 :: (MESH:D009369,Disease) :: ['rectal cancer']


abstract: BACKGROUND: @entity256 rate is lower after @entity3446 -eluting stent (SES) implantation than after @entity1702 ( @entity1702 ) implantation. We evaluated the impact of SES implantation on immediate and 12-month outcome in @entity6 @entity1 with multivessel @entity453 (MVD). METHODS: From April 2002 to September 2003, 100 consecutive @entity6 @entity1 with MVD without previous myocardial revascularization underwent successful elective percutaneous coronary intervention (PCI) with SES on native coronary arteries at our institutions. A group (n = 122) of consecutive @entity6 @entity1 with MVD treated with @entity1702 implantation ( @entity1702 group) for de novo lesions was selected from our database and matched with the SES group. Major adverse @entity299 (MACEs) during hospital stay and at follow-up included nonfatal @entity583 , @entity204 , bypass surgery, and re-PCI. RESULTS: At 12 +/- 4 months, MACEs occurred in 25% of @entity1 in the SES group and in 44% of those in the @entity1702 group (P = .003, OR .72, 95% CI 0.57-0.91). Need for repeat intervention (re-PCI or bypass surgery) occurred in 17% of @entity1 in the SES group and in 41% of those in the @entity1702 group (P < .001, OR .67, 95% CI 0.52-0.86). No significant difference in the rate of @entity204 and @entity583 was observed. In the SES group, the independent predictors of MACEs at follow-up were premature clopidogrel discontinuation (hazard ratio 20.62, 95% CI 1.60-264.97, P = .020) and @entity740 (hazard ratio 4.73, 95% CI 1.99-11.25, P = .0004). CONCLUSIONS: As compared with @entity1702 implantation, SES implantation favorably influences outcome in @entity6 @entity1 with MVD, mainly by reducing the need for new revascularization.

title: Sirolimus-eluting stent implantation in XXXX @entity1 with multivessel @entity453 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic']

entities_list: @entity256 :: ('MESH:D023903', 'Disease') :: ['Restenosis']

entities_list: @entity740 :: ('MESH:D051436', 'Disease') :: ['chronic renal insufficiency']

entities_list: @entity1702 :: ('MESH:D013651', 'Disease') :: ['BS', 'bare metal stent']

entities_list: @entity3446 :: ('MESH:D020123', 'Chemical') :: ['sirolimus']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetic']


abstract: BACKGROUND: Upper gastrointestinal (UGI) complications are a well-recognized risk of NSAID treatment, requiring preventive measures in high-risk @entity1 . Adherence to gastroprotective agents (GPAs) in NSAID users has been suggested to be suboptimal. AIM: To investigate the association between adherence to GPAs (proton pump inhibitors or H(2)-receptor antagonists) and the risk of NSAID-related UGI @entity1066 or @entity548 in high-risk @entity1 . METHODS: A population-based nested case-control study was conducted within a cohort of new NSAID users with at least one risk factor for a NSAID-related @entity344 , identified in the Dutch IPCI database during 1996-2005. Adherence to GPAs was calculated as the proportion of NSAID treatment days covered (PDC) by a GPA prescription. Multivariate conditional logistic regression analysis was used to calculate odds ratios with 95% confidence intervals (95% CI). RESULTS: Fifteen percent of the non-selective NSAID users received GPAs. The risk of a NSAID-related @entity344 among NSAID users increased 16% for every 10% decrease in adherence. Compared to @entity1 with a PDC of >80%, @entity1 with PDCs of 20-80% and <20% had a 2.5-fold (95% CI: 1.0-6.7) respectively 4.0-fold (95% CI: 1.2-13.0) increased risk. CONCLUSION: There is a strong inverse relationship between adherence to GPAs and the risk of UGI complications in high-risk NSAID users.

title: Adherence to gastroprotection and the risk of NSAID-related upper XXXX and @entity548 .

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['UGI complication']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['haemorrhage']

answer: @entity344 :: (MESH:D005767,Disease) :: ['gastrointestinal ulcers']


abstract: INTRODUCTION: Robots help to intensify motor rehabilitation of the upper and lower limbs after @entity64 . This article presents controlled studies relating to this topic, and an overview. METHODS: A search was carried out for relevant randomized controlled trials, published between 1980 and 2007, on Medline (PubMed), Embase, and CINHAL. RESULTS: Two studies showed benefit for an electromechanical gait trainer, with significantly more @entity1 resuming walking as compared to conventional physiotherapy. Two studies showed no evidence of benefit for an exoskeleton-based system. A pooled analysis was not conducted due to the small numbers of studies and high heterogeneity. In arm/hand rehabilitation a number of unilateral or bilateral end-effector based systems proved effective in @entity1 with @entity64 , and a simple one-dimensional system and a passive exoskeleton system proved effective in @entity1 with chronic symptoms. DISCUSSION: Robot-assisted motor rehabilitation after @entity64 appears promising. More trials, including comparative studies, are mandatory. The robot cannot be considered a substitute for the @entity1 -therapist relationship.

title: Robot-assisted upper and lower limb rehabilitation after XXXX : walking and arm/hand function.

answer: @entity64 :: (MESH:D020521,Disease) :: ['stroke']


abstract: 11 @entity1 suffering from an isolated @entity1210 during fractionated radiotherapy were treated with @entity1261 ( @entity1261 ). 4 of the @entity1 received radiotherapy alone, and 7 @entity1 received concomitant chemotherapy. @entity1261 treatment was initiated at the occurrence of @entity1210 and maintained for the duration of radiotherapy. The applied daily dose was 5 micrograms/kg subcutaneously. 10 of the 11 treated @entity1 reacted with an increased leucocyte count, from an average of 1342 leucocytes per microliter (+/- 502/microliters) to 24,568 leucocytes per microliter (+/- 950/microliters). Neutrophil counts increased on average from 64.9% (+/- 13.9%) to 91.1% (+/- 2.3%) (n = 7). In 1 @entity1 @entity882 occurred during the continued radiotherapy. 1 other @entity1 reacted with an unexplained fall of leucocytes after two doses of @entity1261 and one fraction of mediastinal irradiation. Side-effects observed during @entity1261 treatment consisted of mild @entity158 (1/11) and transient increases of serum alkaline phosphatase levels (4/11). Our observations indicate that @entity1261 treatment is well tolerated during continuous fractionated radiotherapy. Therefore, we conclude that @entity1261 can be used clinically to alleviate @entity1398 caused by radiotherapy or by combined radio-chemotherapy.

title: Granulocyte colony-stimulating factor treatment of XXXX during fractionated radiotherapy.

entities_list: @entity1261 :: ('1440', 'Gene') :: ['G-CSF', 'granulocyte colony stimulating factor']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['bone pain']

entities_list: @entity1210 :: ('MESH:C536227', 'Disease') :: ['leucopenia']

answer: @entity1210 :: (MESH:C536227,Disease) :: ['leucopenia']


abstract: UNASSIGNED: 9540 Background: There is a need to identify new effective chemotherapeutic agents for the treatment of @entity995 ( @entity995 ). METHODS: An institutional protocol (RET5) for the study and treatment of @entity1 with intraocular @entity995 stratified @entity1 into three groups according to laterality and stage of disease. The primary objective of RET5 was to estimate the response of window therapy for @entity1 with bilateral @entity995 in whom at least one eye was Reese-Ellsworth IV or V. Window therapy consisted of 2 courses of @entity1891 and @entity1945 (VT with @entity1261 support). @entity1 with >=  partial response received 3 more courses of VT alternating with 6 courses of @entity1891 and @entity3003 . The @entity1945 dose started at 3 mg/m(2)/day, and was adjusted to attain a target systemic exposure of 140    20 ng/ml*hr. @entity3003 was administered to achieve an area under the curve of 6.5 mg/ml/min. The dose of @entity1891 dose was 0.05 mg/kg if age at diagnosis < 12 months and 1.5mg/m(2) if age at diagnosis > 12 months. RESULTS: From 2/2005 until 6/2010, a total of 27 @entity1 were treated VT window therapy. The median age at enrollment was 8.1 months (range, 0.7 to 22.1 months). Twenty-four of 27 @entity1 (88.9%) responded to the VT window with a response rate 88.9% and a 95% Blyth-Still-Casella CI, 71.3%-96.9%. @entity1503 in the form of grade 4 @entity1398 (n=27), grade 3 @entity417 (n=19) and grade 3-4 @entity882 (n=16) were observed during the VT window. Thirteen @entity1 developed grade 3 non-hematologic @entity137 . @entity1261 support was added after treating 10 @entity1 . @entity1 treated with @entity1261 (n=17) had a significant shorter duration of grade 4 @entity1398 (median, 7 days) compared to @entity1 without @entity1261 (n=10) (median, 24 days) (Wilcoxon rank sum test p<0.0001). CONCLUSIONS: @entity1945 is an effective agent in the treatment of advanced intraocular @entity995 . The use of @entity1261 alleviated @entity137 , especially the duration of grade 4 @entity1398 .

title: The effect of XXXX in @entity995 with manageable @entity137 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity3003 :: ('MESH:D016190', 'Chemical') :: ['Carboplatin', 'carboplatin']

entities_list: @entity1503 :: ('MESH:D006402', 'Disease') :: ['Hematologic toxicity']

entities_list: @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine']

entities_list: @entity1945 :: ('MESH:D019772', 'Chemical') :: ['Topotecan', 'topotecan']

entities_list: @entity995 :: ('MESH:D012175', 'Disease') :: ['intraocular retinoblastoma', 'RB']

answer: @entity1945 :: (MESH:D019772,Chemical) :: ['topotecan']


abstract: BACKGROUND: Acute rhinosinusitis (ARS) has been shown to significantly reduce @entity1 quality of life (QoL). While the QoL in @entity1 with chronic rhinosinusitis has been the subject of intensive research over the last decade, studies measuring the impact of ARS on @entity1 QoL have remained relatively scarce. The aim of this study was to determine the relationship between the QoL and parameters suggestive of acute bacterial rhinosinusitis ( @entity1851 [CRP] levels and positive culture) and to see if measurement of the QoL could be used as an indicator for antibiotic treatment in ARS. METHODS: Eighty @entity1 with ARS were enrolled in the study. A novel QoL instrument for @entity1 with ARS, called Measurement of Acute Rhinosinusitis (MARS) questionnaire, was given to @entity1 at the time of diagnosis. We assessed @entity1 QoL, obtained endoscopically guided cultures from the middle meatus, and measured levels of CRP. The relationship between QoL MARS scores (QoL-Mscores) and CRP was determined using a correlation coefficient. To compare QoL-Mscores, relative to culture-positive and culture-negative @entity1 , the Student's t-test was used. RESULTS: No correlation between the QoL, assessed using the MARS questionnaire, and positive middle meatus culture was demonstrated (P=0.332). A weak correlation was found between QoL-Mscores and CRP values, with a correlation coefficient of 0.221 and P=0.0498. CONCLUSION: No correlation between the QoL in ARS @entity1 and positive culture was found in this study. The clinical significance of the correlation between QoL-Mscores and CRP values in the antibiotic decision making process needs further research.

title: The relationship of XXXX levels and positive culture with quality of life in acute rhinosinusitis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein']

answer: @entity1851 :: (1401,Gene) :: ['C-reactive protein']


abstract: Importance: Childhood @entity4464 and @entity13390 are 2 @entity4939 with a risk of @entity130 for which @entity1423 has been shown. Objectives: To assess the prevalence of @entity4464 and @entity13390 during childhood; to investigate the link between early @entity13390 and @entity4464 later in childhood; and to evaluate the degree of association between parental history of @entity4464 and presence of @entity4464 and @entity13390 in @entity1 . Design, Setting, and @entity1 : Sleep data from a large prospective longitudinal cohort (the Quebec Longitudinal Study of @entity1 Development) of 1940 @entity1 born in 1997 and 1998 in the province were studied from March 1999 to March 2011. Main Outcomes and Measures: Prevalence of @entity13390 and @entity4464 was assessed yearly from ages 11/2 and 21/2 years, respectively, to age 13 years through a questionnaire completed by the mother. Parental history of @entity4464 was also queried. Results: The peak of prevalence was observed at 11/2 years for @entity13390 (34.4% of @entity1 ; 95% CI, 32.3%-36.5%) and at age 10 years for @entity4464 (13.4%; 95% CI, 11.3%-15.5%). As many as one-third of the @entity1 who had early childhood @entity13390 developed @entity4464 later in childhood. The prevalence of childhood @entity4464 increases with the degree of parental history of @entity4464 : 22.5% (95% CI, 19.2%-25.8%) for @entity1 without a parental history of @entity4464 , 47.4% (95% CI, 38.9%-55.9%) for @entity1 who had 1 parent with a history of @entity4464 , and 61.5% (95% CI, 42.8%-80.2%) for @entity1 whose mother and father had a history of @entity4464 . Moreover, parental history of @entity4464 predicted the incidence of @entity13390 in @entity1 as well as the persistent nature of @entity13390 . Conclusions and Relevance: These findings substantiate the strong @entity1423 for the 2 @entity4939 and lend support to the notion that @entity4464 and @entity13390 represent 2 manifestations of the same underlying pathophysiological entity.

title: Childhood @entity13390 : A Longitudinal Study of Prevalence and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Child', 'children', 'Participants']

entities_list: @entity1423 :: ('MESH:D001791', 'Disease') :: ['familial aggregation']

entities_list: @entity4939 :: ('MESH:D020447', 'Disease') :: ['parasomnias']

entities_list: @entity4464 :: ('MESH:D013009', 'Disease') :: ['somnambulism', 'sleepwalking']

entities_list: @entity13390 :: ('MESH:D020184', 'Disease') :: ['sleep terrors']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['serious injury']

answer: @entity1423 :: (MESH:D001791,Disease) :: ['Familial Aggregation']


abstract: 1. Two polydeoxyribonucleotides, produced by the controlled hydrolysis of DNA of @entity1 lung (defibrotide and its lower molecular weight fraction, P.O. 085 DV), were studied for their ability to modify the release of @entity3542 and the coronary flow in perfusates collected from isolated, normally perfused hearts of @entity840 and from hearts subjected to regional ischaemia and reperfusion. 2. In @entity840 normally perfused hearts, both @entity3523 (DFT) and its fraction, P.O. 085 DV, increase the amount of @entity3542 appearing in perfusates in a concentration-dependent fashion. At the highest concentration studied (10(-6) M), P.O. 085 DV was more effective than DFT. A concomitant increase in the coronary flow was observed. 3. The increase in @entity3542 in perfusates and the increase in coronary flow induced by both DFT and P.O. 085 DV were significantly reduced by @entity7293 ( @entity7293 , 10(-4) M), an inhibitor of @entity842 synthase (NOS). 4. The endothelium-dependent vasodilator, @entity934 ( @entity1617 ), enhances the formation of @entity3542 and the coronary flow. Both the increase in coronary flow and in the formation of @entity3542 were significantly reduced by @entity7293 (10(-4) M). 5. In @entity840 hearts subjected to ischaemia and reperfusion, the effect of both compounds in increasing the amount of @entity3542 in perfusates was more evident and more pronounced with P.O. 085 DV. 6. Reperfusion-induced @entity943 were significantly reduced by both compounds to the extent of complete protection afforded by compound P.O. 085 DV. 7. The cardioprotective and antiarrhythmic effects of DFT and P.O. 085 DV are discussed.

title: Polydeoxyribonucleotides and XXXX release from @entity840 hearts during ischaemia and reperfusion.

entities_list: @entity1 :: ('9606', 'Species') :: ['mammalian']

entities_list: @entity3523 :: ('MESH:C036901', 'Chemical') :: ['defibrotide']

entities_list: @entity3542 :: ('CHEBI:16301', 'Chemical') :: ['nitrite']

entities_list: @entity840 :: ('10141', 'Species') :: ['guinea-pig', 'guinea-pigs']

entities_list: @entity7293 :: ('CHEBI:28229', 'Chemical') :: ['L-NMMA', 'NG-monomethyl-L-arginine']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmias']

entities_list: @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']

answer: @entity842 :: (MESH:D009569,Chemical) :: ['nitric oxide']


abstract: @entity1 @entity29594 kinase ( @entity45211 ), which possesses both 5'-DNA kinase and 3'-DNA phosphatase activities, is a DNA repair enzyme required for processing and rejoining of single- and double-strand-break termini. Full-length @entity45211 was subjected to sedimentation and spectroscopic analyses in association with its ligands, a 20-mer oligonucleotide, @entity855 , and @entity860 - @entity26864 (a nonhydrolyzable analogue of @entity855 ). Sedimentation equilibrium measurements indicated that @entity45211 was a monomer in the presence and absence of the ligands. Circular dichroism measurements revealed that the ligands induced different conformational changes in @entity45211 , although @entity860 - @entity26864 induced the same conformational changes as @entity855 . @entity1050 also indicated that the oligonucleotide could bind to the protein- @entity860 - @entity26864 complex. Protein-ligand binding affinities and stoichiometries were determined by measuring changes in protein intrinsic fluorescence. Titrating @entity45211 with the oligonucleotide indicated tight binding with a K(d) value of 1.3 microM and with 1:1 stoichiometry. A 5'-phosphorylated oligonucleotide with the same sequence exhibited an almost 6-fold lower affinity (K(d) value, 7.2 microM). @entity855 and @entity860 - @entity26864 bound with high affinity (K(d) values, respectively, of 1.4 and 1.6 microM), and the observed binding stoichiometries were 1:1. Furthermore, the nonphosphorylated oligonucleotide was able to bind to @entity45211 in the presence of @entity860 - @entity26864 with a K(d) value of 2.5 microM, confirming the formation of a ternary complex. This study provides the first direct physical evidence for such a ternary complex involving a polynucleotide kinase, @entity860 - @entity26864 , and an oligonucleotide, and supports a reaction mechanism in which @entity855 and DNA bind simultaneously to the enzyme.

title: Spectroscopic studies of DNA and @entity855 binding to XXXX polynucleotide kinase: evidence for a ternary complex.

entities_list: @entity29594 :: ('CHEBI:15986', 'Chemical') :: ['polynucleotide']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: AIM: The aims of the present study were to investigate the effectiveness of exercise intervention provided by a medical support team specializing in lifestyle-related diseases in the treatment of elderly @entity1746 and to examine the influence of bodyweight decrease on changes in the evaluation indexes. METHODS: @entity1 were 61 @entity1 (57 @entity1 and 4 @entity1 , aged 68.3    9.6 years) with @entity1746 (109 @entity2720 ) and either one or more of the following diseases: @entity28 , @entity209 and @entity164 2 @entity6 . Indexes relating to @entity209 , @entity74 , lifestyle activity level and health-related quality of life (HRQOL) were obtained before and after exercise intervention. RESULTS: The numbers of @entity1 with @entity28 , @entity209 , @entity164 2 @entity6 , gonarthrosis and @entity570 were 56, 49, 32, 56 and 9, respectively. The mean intervention period was 4.7    1.6 months (2-10.8 months). Indexes relating to @entity209 and @entity74 , activity level and HRQOL were all significantly improved after intervention (P < 0.05). Bodyweight decreased by 10.3% and showed a correlation with other evaluated items. Five explanatory variables were extracted through multiple regression analysis that bodyweight reduction rate was set as the criterion variable: changes of bodyweight, body mass index, percent body fat, glycated hemoglobin and total energy expenditure per bodyweight. CONCLUSION: The exercise intervention provided by our medical support team clearly improved indexes relating to @entity209 and @entity74 . In addition, decreased bodyweight was related to improvements in metabolic factors, motor function and HRQOL.

title: Effects of physical exercise prescribed by a medical support team on elderly @entity1746 combined with @entity209 and/or XXXX 2 @entity6 .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Participants', 'men']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic diseases', 'metabolic syndrome']

entities_list: @entity1746 :: ('MESH:D020335', 'Disease') :: ['lower extremity osteoarthritis']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['orthopedic disorders']

entities_list: @entity2720 :: ('MESH:D007592', 'Disease') :: ['total diseased joints']

entities_list: @entity570 :: ('MESH:D015207', 'Disease') :: ['coxarthrosis']

answer: @entity164 :: (MESH:D017827,Disease) :: ['type']


abstract: The feasibility of adding both the multidrug resistance modulator @entity205 (CsA) and @entity1261 ( @entity1261 ) to a standard salvage regimen of @entity8779 (IDA) and @entity2592 was evaluated in @entity1 with resistant or relapsed @entity3052 and @entity2590 . Three @entity1 received IDA 12 mg/m2/day, the next four @entity1 9 mg/m2/day. The dose of CsA was 16 mg/kg/day. Six @entity1 showed @entity7895 expression and none @entity11092 expression. Grade III or IV @entity137 (CTC-NCIC criteria) was registered in six @entity1 for gastrointestinal, two @entity1 for cardiovascular and one @entity1 for @entity16 . Three @entity1 died in @entity509 and three @entity1 showed @entity1778 . Three control @entity1 were treated with IDA 12 mg/m2/day and @entity2592 , but no CsA and @entity1261 . The plasma IDA and @entity47478 (ida-ol) area under the curve's of @entity1 treated with @entity11059 12 mg/m2 plus CsA were higher (P< 0.05) than in controls. Cellular IDA concentrations were almost similar, but cellular ida-ol concentrations were significantly higher (P < 0.05) in the presence of CsA than in controls. We conclude that the @entity137 either with IDA 12 or 9 mg/m2/day was too high. The modulating effect of CsA was mainly based on changes in plasma kinetics of IDA and ida-ol, although ida-ol cellular clearance was delayed in the presence of CsA.

title: @entity205 increases cellular XXXX and @entity47478 concentrations in relapsed or refractory AML mainly due to reduced systemic clearance.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity1261 :: ('1440', 'Gene') :: ['G-CSF', 'granulocyte colony-stimulating factor']

entities_list: @entity8779 :: ('MESH:D015255', 'Chemical') :: ['idarubicin']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological complications']

entities_list: @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndrome']

entities_list: @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytarabine']

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia']

entities_list: @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporin']

entities_list: @entity509 :: ('MESH:C538429', 'Disease') :: ['hypoplasia']

entities_list: @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemic regrowth']

entities_list: @entity47478 :: ('MESH:C054440', 'Chemical') :: ['idarubicinol']

answer: @entity8779 :: (MESH:D015255,Chemical) :: ['idarubicin']


abstract: A feature of the @entity35 brain @entity1246 transporter @entity44297 , and other members of the neurotransmitter transporter family, is its regulated redistribution between intracellular locations and the plasma membrane. Recent studies have focused upon defining the signaling molecules that facilitate this redistribution. Agents that promote direct @entity669 phosphorylation of @entity44297 promote a relative increase in surface @entity44297 levels, and this results from a slowing of the transporter internalization rate. Agents that act to increase @entity7131 ( @entity7131 ) activity promote a relative decrease in surface @entity44297 levels; whether this effect is caused by direct transporter phosphorylation is unknown. The opposing actions of @entity669 kinase activity and @entity7131 activity raise the possibility that the subcellular distribution of @entity44297 is associated with mutually exclusive transporter phosphorylation events. The present experiments show that @entity44297 is phosphorylated on @entity563 residues in a @entity7131 -dependent manner, but this state is only revealed when @entity44297 @entity669 phosphorylation is eliminated or greatly reduced. The relative levels of @entity563 phosphorylation and @entity669 phosphorylation are negatively correlated. The amount of @entity563 phosphorylation is regulated by agents that affect @entity669 phosphorylation, and vice versa. In addition, the ability of agents that affect @entity669 kinase activity to regulate @entity44297 @entity563 phosphorylation requires a change in its @entity669 phosphorylation state. These data support the ideas that @entity44297 can exist in either of two mutually exclusive phosphorylation states and that the relative abundance of these states determines in part the relative subcellular distribution of the transporter.

title: Regulation of a @entity1246 transporter by reciprocal @entity669 and XXXX phosphorylation.

entities_list: @entity1246 :: ('MESH:D005680', 'Chemical') :: ['gamma-aminobutyric acid']

entities_list: @entity7131 :: ('MESH:D020151', 'Disease') :: ['protein kinase C', 'PKC']

entities_list: @entity563 :: ('CHEBI:17822', 'Chemical') :: ['serine']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

answer: @entity563 :: (CHEBI:17822,Chemical) :: ['serine']


abstract: OBJECTIVE: To investigate whether specific frontal regions have a tendency to generate @entity7158 ( @entity7158 ) and others focal spikes and to determine the regions most involved when @entity7158 occur; to assess the relationships between the extent of electroencephalography (EEG) discharges and the extent of metabolic changes measured by EEG/functional magnetic resonance imaging (fMRI). METHODS: Thirty-seven @entity1 with @entity302 ( @entity302 ) with frontocentral predominance underwent EEG/fMRI. @entity1 were divided into a Focal (20 @entity1 ) group with focal frontal spikes and a WBSD group (17 @entity1 ). Maps of hemodynamic responses related to @entity302 were compared between the two groups. RESULTS: The mean number    SD of @entity302 in the Focal group was 137.5      38.1 and in the WBSD group, 73.5      16.6 (p  =  0.07). The volume of hemodynamic responses in the WBSD group was significantly larger than in the Focal group (mean, 243.3      41.1 versus 114.8      27.4  cm(3) , p  =  0.01). Maximum hemodynamic responses occurred in both groups in the following regions: dorsolateral prefrontal, mesial prefrontal, cingulate, and supplementary motor cortices. Maxima in premotor and motor cortex, frontal operculum, frontopolar, and orbitofrontal regions were found only in the Focal group, and maxima in thalamus and caudate only occurred in the WBSD group. Thalamic responses were significantly more common in the WBSD group (14/17) than in the Focal group (7/20), p  =  0.004. Deactivation in the default mode network was significantly more common in the WBSD group (14/17) than in the Focal group (10/20), p  =  0.04. SIGNIFICANCE: The spatial distribution and extent of blood @entity26 level-dependent (BOLD) responses correlate well with electrophysiologic changes. Focal frontal spikes and @entity7158 are not region specific in the frontal lobe, and the same frontal region can generate focal and generalized discharges. This suggests that widespread discharges reflect widespread epileptogenicity rather than a focal discharge located in a region favorable to spreading. The thalamus plays an important role in bilateral synchronization.

title: BOLD responses related to focal spikes and XXXX generated in the frontal lobe.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity7158 :: ('MESH:D009378', 'Disease') :: ['widespread bilateral synchronous discharges', 'WBSDs']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['interictal epileptic discharges', 'IEDs']

answer: @entity7158 :: (MESH:D009378,Disease) :: ['widespread bilateral synchronous discharges']


abstract: Since our initial experience on April 28, 1989, a total of nine @entity1 have received treatment for @entity438 using cardiopulmonary bypass with @entity2332 and @entity1167 . The following data summarize our findings associated with these @entity1 . The average @entity1 's age was 46 years (range: 16 to 59 years of age). Seven @entity1 were female, two were male. The procedure required approximately eight hours to complete with an average cardiopulmonary bypass time of 104 minutes (range: 60 to 140 minutes). Circulatory arrest time averaged 26 minutes (range, 12 to 45 minutes) with an average of 30 minutes (range: 10 to 62 minutes) required to cool the @entity1 to below 18 degrees C (64 degrees F). An average of 54 minutes (range: 28 to 81 minutes) was required to warm the @entity1 to a bladder temperature of 36 degrees C (96.8 degrees F). During the cooling period, five @entity1 went into asystole spontaneously, four @entity1 required bolus of 20 mEq of @entity4337 , and upon rewarming, spontaneous defibrillation occurred in six @entity1 . Three @entity1 were defibrillated without difficulty with external shock. The average number of blood products administered in each of the nine @entity1 was 3.6 units of packed red blood cells, 3 units of fresh frozen plasma, and 6.5 units of platelets. Six @entity1 recovered postoperatively without complication, and the recovery of three @entity1 was affected by the complex anatomical location of the @entity439 . Cardiopulmonary bypass with @entity2332 and @entity1167 offers an alternative approach to the treatment of @entity438 considered inoperable by conventional techniques. The effectiveness of each procedure depends on the collaborative efforts of every member of the perioperative nursing team, the neurosurgical team, the cardiac surgical team, the neuroanesthesiology team, and the perfusionists. Careful planning and anticipation at every stage of the surgery can reduce surgical time, cardiopulmonary bypass time, and most importantly, @entity1167 time.

title: XXXX repair. Incorporating cardiopulmonary bypass and neurosurgery.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['giant aneurysm']

entities_list: @entity1167 :: ('MESH:D006323', 'Disease') :: ['circulatory arrest']

entities_list: @entity4337 :: ('MESH:D011189', 'Chemical') :: ['potassium chloride']

entities_list: @entity2332 :: ('MESH:D007035', 'Disease') :: ['deep hypothermia']

entities_list: @entity438 :: ('MESH:D002532', 'Disease') :: ['giant cerebral aneurysms', 'giant cerebral aneurysm']

answer: @entity438 :: (MESH:D002532,Disease) :: ['Giant cerebral aneurysm']


abstract: In the EORTC Radiotherapy Group, the feasibility of @entity227 ( @entity227 ) was tested in a pilot study from 1978 to 1980. Three daily fractions of 1.6 Gy were given (4 h interval) during 2 weeks (total dose 48 Gy), with a boost to about 70 Gy after 3-4 weeks. In 53 of the 179 @entity1 , @entity8712 was given on every irradiation day (1 g/m2, total 13-14 g/m2). Data on tolerance and early treatment results were published previously; results with a minimum follow-up period of 3 years are now available. Survival (actuarial is 21% and @entity5 control was obtained in 34% of @entity1 ; no significant differences were seen between the subregions in the @entity135 area. Survival is better in @entity1 treated with @entity8712 (probably due to selection), but locoregional control was identical as in @entity1 treated without the sensitizer. In February 1984, 38 @entity1 were alive, 35 without evidence of @entity5 (5 after rescue surgery). @entity3 were seen in 16% and a second @entity5 in 7% of @entity1 . Seventeen @entity1 (9%) died of causes, possibly related to treatment; @entity39 was observed in 8 (4 with @entity5 ). Late effects in the long survivors were comparable to what is usually seen after high-dose radiotherapy.

title: Late results of @entity227 ( @entity227 ) with @entity8712 in advanced @entity5 of the XXXX . A pilot study of the EORTC radiotherapy group.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['multiple fractions per day', 'MFD']

entities_list: @entity8712 :: ('MESH:D008920', 'Chemical') :: ['misonidazole']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'locoregional tumor', 'local tumor']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['Metastases']

answer: @entity135 :: (MESH:D006258,Disease) :: ['head and neck']


abstract: Many cardiologists consider it reasonable to assume in clinical practice that percutaneous coronary intervention using drug-eluting stents ought to be considered equivalent, if not superior, to bypass surgery. In the absence of a definitive clinical trial to support this view, how should the prudent, cutting-edge cardiologist proceed? OBJECTIVES: This study assessed the geographical differences in target vessel revascularization (TVR) after percutaneous coronary intervention (PCI) in the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) trial. BACKGROUND: An aggressive approach to PCI is more common in the U.S. than in other countries. The impact of this approach on @entity256 outcomes has not been studied. METHODS: Using the PRESTO trial, we compared nine-month @entity63 TVR after PCI in U.S.-treated @entity1 (n = 5,026) with rates in other countries (n = 6,458). We defined TVR as repeat intervention for @entity662 /positive stress test. Additionally, angiographic @entity256 (> or =50% narrowing or > or =50% loss of gain at nine-month follow-up) was compared between U.S. and non-U.S. @entity1 within the prespecified angiographic subset (n = 2,823). Regression models were developed to adjust for clinical and lesion-related characteristics. RESULTS: Higher rates of TVR (18% vs. 11%), and angiographic @entity256 (65% vs. 48%) were observed in @entity1 treated in the U.S. as compared with the other @entity1 (p < 0.01 for both comparisons). @entity1 treated in the U.S. were more likely to be female, @entity6 , not currently smoking, to have @entity1459 , and to have a prior PCI. In U.S. @entity1 , lesions tended to be longer, but less likely to be American College of Cardiology/American Heart Association class C. After adjusting for clinical and angiographic variables, PCI in the U.S. was still associated with @entity101 and @entity63 TVR. CONCLUSIONS: Angiographic @entity256 and @entity63 -driven TVR rates were higher in @entity1 treated in the U.S. The difference could only partially be explained by the higher prevalence of measured adverse clinical and angiographic features.

title: Geographical differences in the rates of angiographic XXXX and @entity63 -driven target vessel revascularization after percutaneous coronary interventions: results from the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) Trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['chest pain']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['increased angiographic restenosis']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia', 'ischemic']

entities_list: @entity256 :: ('MESH:D023903', 'Disease') :: ['restenosis']

entities_list: @entity1459 :: ('MESH:D000789', 'Disease') :: ['unstable angina']

answer: @entity256 :: (MESH:D023903,Disease) :: ['restenosis']


abstract: The vast majority of published papers on the efficacy of extracorporeal shockwave therapy (ESWT) have come up with rather controversial results in @entity1 with @entity3444 . The AIM of the present study was to investigate the effect of radial shock wave therapy in @entity1 with chronic @entity3444 . MATERIAL AND METHODS: Twenty-one @entity1 were included in the study (mean age 51.29 +/- 2.02 yrs, mean duration of symptoms 10.14 +/- 1.11 mos). Radial shock wave therapy was administered in five sessions. Total number of shocks per session was 2500 at a pressure of 2.5 bars. Visual analog scale (VAS) and a modification of the clinical rating system of the American Orthopedic Foot and Ankle Society (AOFAS) were used for outcome measurement. The @entity1 were assessed before treatment and followed up 3, 6, and 12 months after end of treatment. RESULTS: Statistically significant improvement in @entity158 and functional capacity was found after completion of treatment in comparison with baseline; the improvement was preserved throughout a one-year follow-up. VAS mean score for @entity158 showed changes in @entity158 while walking the first few steps in the morning from 6.28 +/- 0.4 before therapy to 2.85 +/- 0.48 after treatment and to 1.52 +/- 0.31 at 3 months, to 1.09 +/- 0.25 at 6 months, and to 0.52 +/- 0.14 at 12 months of follow up (p <0.001). Similar dynamics was observed in @entity158 intensity during daily activities, at rest, in the evening and upon compression. The AFOAS score showed a statistically significant reduction in @entity158 --from 11.90 +/- 2.35 at baseline to 31.90 +/- 1.48 after the end of interventions (p < 0.001), and to 39.52 +/- 0.47 at one year of follow-up (p < 0.001). The mean values of the evaluation reflecting activity limitations and support requirements increased from 3.85 +/- 0.42 to 7.85 +/- 0.46 after treatment and to 9.71 +/- 0.19 at one year of follow up (p < 0.001). Similar dynamics was seen in the maximum walking distance and walking surfaces. Gait abnormalities changed from 3.43 +/- 0.50 at baseline to 6.28 +/- 0.59 after treatment (p < 0.001). CONCLUSION: Based on the results of this study we could conclude that radial shock wave therapy is a safe non-invasive method of treatment. Our preliminary findings indicate that it could be an effective treatment of choice for @entity1 with @entity3444 that is recalcitrant to other conservative treatment modalities.

title: Radial shock wave therapy for XXXX : a one year follow-up study.

entities_list: @entity3444 :: ('MESH:D036981', 'Disease') :: ['chronic plantar fasciitis', 'plantar fasciitis', 'proximal plantar fasciitis']

answer: @entity3444 :: (MESH:D036981,Disease) :: ['plantar fasciitis']


abstract: @entity1740 can occur in the elderly as a result of natural anatomical and physiological changes or greater exposure to pathological conditions in the aging, affecting communication and quality of life. Nevertheless, data about the prevalence of @entity1740 in this phase of life are not well known in a population-based perspective. The aim of the present systematic review was to identify the prevalence of @entity74 in @entity1 aged 60  years or more in population-based studies. A systematic review was undertaken in eleven electronic databases based on preferred reporting items for systematic reviews and meta-analysis statement (PRISMA) criteria. The methodological quality of the studies was analyzed with strengthening the reporting of observational studies in epidemiology (STROBE) directives. The search was conducted independently by two researchers. Four articles satisfied the criteria of eligibility. The prevalence of @entity74 in the general population aged 60  years or more ranged from 4.8 to 29.1  %. The studies were different in terms of the methodological procedures and the STROBE directives were not completely satisfied by any of the articles selected. The prevalence of @entity74 in the general elderly population ranged from low to moderate in population-based studies. The methodological discrepancies of the studies compromised the reliability of the estimated data. Upgrading the methodological quality of studies and designing a short, valid and easy-to-use functional voice-related instrument are urgently required in health surveys to determine the prevalence of @entity74 among elderly individuals.

title: Prevalence of XXXX in the elderly: a systematic review of population-based studies.

entities_list: @entity1740 :: ('MESH:D014832', 'Disease') :: ['voice disorders', 'Voice disorders']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['vocal disorders']

answer: @entity1740 :: (MESH:D014832,Disease) :: ['voice disorders']


abstract: OBJECTIVES: The aim of this work was to study the action of @entity4443 on the growth of @entity1 mammary @entity5 cells MCF-7. STUDY DESIGN: The growth of the cells was measured by incorporation of @entity665 . The action of @entity4352 (LT)B4, LTD4, LTC4, LTE4 or @entity3899 (AA) was tested in @entity1 mammary @entity5 cells MCF-7 in vitro. RESULTS: LTB4 or LTD4 but not LTC4 or LTE4 reduced significant incorporation of @entity665 in MCF-7 cells up to 52% or 56% respectively, when administered in concentrations 0.1-1000 pM. Agents in concentrations of 0.01 pM or 10000 pM did not effect @entity665 incorporation. We have shown, that MCF-7 cells synthesise LTB4 when treated with @entity460 ionophor @entity3365 (10 microM). Leukotriene-antagonist @entity8766 (10 microM) lifts inhibitory effects of LTB4 or LTD4. @entity1426 (10 microM) inhibits @entity665 incorporation up to 72%. @entity1437 inhibitor @entity20463 (100 nM) lifts the inhibitory effect of @entity3899 . CONCLUSIONS: LTB4 or LTD4 inhibits MCF-7 @entity0 cell growth. LT-receptors mediate the growth-inhibitory effect of LTB4 or LTD4.

title: Influence of @entity4443 on in vitro growth of XXXX mammary carcinoma cell line MCF-7.

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity4443 :: ('MESH:D015289', 'Chemical') :: ['leukotrienes']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity1426 :: ('MESH:D016718', 'Chemical') :: ['Arachidonic acid']

entities_list: @entity4352 :: ('CHEBI:25029', 'Chemical') :: ['leukotriene']

entities_list: @entity665 :: ('CHEBI:53526', 'Chemical') :: ['3H-thymidine']

entities_list: @entity3899 :: ('CHEBI:32395', 'Chemical') :: ['arachidonate']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: OBJECTIVES: To demonstrate aggressive management of neck @entity3 adherent to the internal or common carotid artery using sound oncologic principles while minimizing the significant risk of complications. STUDY DESIGN: Our 13 year experience of treating @entity1 with recurrent or residual neck @entity3 adherent to the internal or common carotid artery was retrospectively reviewed. METHODS: Angiography was used in @entity1 who demonstrated fixation of the carotid artery on examination or imaging, followed by balloon test occlusion and single photon emission computer tomography (SPECT) scanning. The majority of carotid resections were reconstructed with a vein graft, especially if there was insufficient collateral cerebral circulation. Radical resection of the soft tissue including the carotid artery was performed followed by 15 to 20 Gray of electron beam delivered directly to the deep tissue. More recently, the carotid has been permanently occluded preoperatively, if possible. The assessment of the cerebral circulation and management of the carotid artery were analyzed as was survival, site of recurrence, and complications. RESULTS: Fifty-eight charts were reviewed. The majority of @entity1 (41) had their carotid artery reconstructed at time of resection, and the remaining had either the artery ligated or permanently occluded preoperatively. @entity64 occurred in 11 @entity1 . The median disease-specific survival was 12 months, with 24% of @entity1 dying from distant @entity3 . CONCLUSIONS: The high risk of complications, loss of life's quality, and mortality must be balanced against the natural history of the disease if left untreated. The decision is a heavy burden for the @entity1 , family, and head and neck surgeon.

title: Management of neck XXXX with carotid artery involvement.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['Strokes']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

answer: @entity3 :: (MESH:D009362,Disease) :: ['metastasis']


abstract: BACKGROUND: @entity3562 seems to be frequent after renal transplantation. No study so far has assessed the role of @entity1255 ( @entity5784 ) associated with @entity2299 in Brazil. OBJECTIVE: To determine the prevalence of @entity3562 (serum @entity5784 >15 mmol/l) in stable @entity8 and to evaluate the role of serum lipids and graft function in serum @entity5784 levels. METHODS: One hundred and five stable @entity8 were evaluated, considering age, post-transplant time, @entity165 levels, graft function, @entity644 , and @entity205 (analyzed using multiple linear regression). The prevalence of @entity3562 was 74.3%. @entity1 were further divided into two groups, hyper (total @entity165 >200 mg/dl, LDL- @entity165 >130 mg/dl) and normocholesterolemic. RESULTS: @entity753 recipients were older, had shorter post-transplant time, lower endogenous @entity1011 clearance, and higher @entity644 and @entity5784 serum levels. @entity1 with @entity3562 had statistically significantly higher serum @entity1674 and poorer graft function, and their LDL- @entity165 also tended to be higher. A positive correlation was found between serum @entity1011 and @entity5784 levels (r = 0.32, P = 0.01). Multiple regression analysis revealed that both @entity2299 and renal function independently affect @entity5784 values. CONCLUSION: We observed a high prevalence of @entity3562 in @entity8 , especially in @entity753 , suggesting that worse graft function may influence serum @entity5784 and @entity165 levels negatively. Further studies should investigate if this adverse metabolic profile is associated with higher cardiovascular mortality in the long term.

title: Serum @entity1255 levels in XXXX with and without hypercholesterolemia.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients']

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal transplant recipients']

entities_list: @entity753 :: ('OMIM:143890', 'Disease') :: ['hypercholesterolemic', 'Hypercholesterolemic']

entities_list: @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia']

entities_list: @entity1255 :: ('MESH:D006710', 'Chemical') :: ['homocysteine']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity3562 :: ('MESH:D020138', 'Disease') :: ['Hyperhomocysteinemia', 'hyperhomocysteinemia']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity8 :: (MESH:D007674,Disease) :: ['renal transplant recipients']


abstract: PURPOSE: To report an unusual case of ocular @entity3191 presenting as sclerouveitis. METHODS: A 53-year-old @entity1 presented with @entity158 , @entity18368 and was initially treated with antivirals and corticosteroids for what was presumed to be isolated @entity5517 with @entity1333 . When she failed to improve the conjunctiva was biopsied and characterized by immunohistochemical and molecular methods. The literature regarding conjunctival @entity784 as well as @entity706 mimicking @entity3170 is reviewed. RESULTS: Biopsies of a scleral/conjunctival nodule from the right eye were obtained on 2 occasions, the second of which revealed the presence of intermediate to large size lymphocytes that were CD3, T-cell intracellular antigen 1 and Granzyme B positive but CD56 and @entity9653 negative. Polymerase chain reaction showed clonal T-cell receptor gamma rearrangements in DNA samples isolated from biopsy tissue. Another biopsy was obtained from a @entity3137 in the oropharynx, which was shown to contain an identical T-cell receptor gamma rearrangement. These results led to the diagnosis of @entity3191 . @entity784 have been reported in two other @entity1 both of which also had involvement of upper airway structures. Five other reports of @entity706 mimicking @entity3170 are discussed. CONCLUSIONS: @entity3191 should be considered in the differential diagnosis of @entity1 who present with sclerouveitis of unknown etiology unresponsive to conventional therapy. If a conjunctival @entity784 is identified a systemic evaluation for @entity706 with particular attention to the upper airway is justified.

title: XXXX presenting as sclerouveitis.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patients']

entities_list: @entity5517 :: ('MESH:D015817', 'Disease') :: ['ocular HSV infection']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma', 'lymphomas']

entities_list: @entity1333 :: ('MESH:D014657', 'Disease') :: ['vasculitis']

entities_list: @entity3191 :: ('MESH:D016411', 'Disease') :: ['Peripheral T-cell lymphoma', 'peripheral T-cell lymphoma']

entities_list: @entity784 :: ('MESH:D016399', 'Disease') :: ['T-cell lymphomas', 'Conjunctival T-cell lymphomas', 'T-cell lymphoma']

entities_list: @entity9653 :: ('10376', 'Species') :: ['Epstein Barr virus']

entities_list: @entity18368 :: ('MESH:C567079', 'Disease') :: ['unilateral sclerouveitis']

entities_list: @entity3137 :: ('MESH:D009059', 'Disease') :: ['mucosal lesion']

entities_list: @entity3170 :: ('MESH:D015423', 'Disease') :: ['scleritis']

answer: @entity3191 :: (MESH:D016411,Disease) :: ['Peripheral T-cell lymphoma']


abstract: We report the interaction of RA and psychological factors over 2 years in a group of 89 @entity1 with newly established disease. Short-time outcome regarding physical features was fairly good. Disease activity decreased, and disability evaluated by HAQ remained at a low level. Psychological distress as measured by the @entity308 and @entity148 subscales of SCL 90 (Symptom Check List) was not very pronounced and not related to disease state factors. A slight decrease of @entity148 was recorded after 2 years. A new adjustment test was applied. It contained 13 items focused mainly on negative illness effects such as loss of independence, feelings of guilt, and change of social and leisure time activities. Three factors (regret of lost life values, @entity1316 , and acceptance) explained 48% of the variance of the 13 items. The validity of the test was acceptable. The @entity1 ' degree of adjustment changed slowly or not at all during the 2 years.

title: Psychological reactions in XXXX with early rheumatoid arthritis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1316 :: ('MESH:D019964', 'Disease') :: ['dysphoric mood']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVE: To analyze the effect of @entity1144 on new-onset @entity385 events among @entity6 @entity1 in the Kailuan Group. METHODS: This was a prospective cohort study. In a total of 101 510 employees who had been carried out a healthy examination in Kailuan Group from Jul. 2006 to Oct. 2007. 8 306 @entity6 @entity1 were selected. According to the baseline waist measurement, the observed population was divided into two groups-with @entity1144 or without. The total period of follow-up was 38-53 (48.05    3.09) months. RESULTS: 1) Mean age, BMI, the levels of @entity13519 , @entity13520 , pulse pressure, FPG, TC, LDL-C, @entity414 significant increased in the @entity1144 group were higher than in the non- @entity28 group (P < 0.01). 2) The incidence of new onset @entity385 in @entity28 group was higher than that in the non- @entity28 group (3.1% vs. 1.6%, 6.8%, P < 0.01;3.3% vs. 1.7%, P < 0.01 in male respectively. 3) Results from the multiple logistic regression analysis showed that, compared with the non- @entity28 group, the @entity28 group had an increase of relative risk (RR) on new onset @entity385 events after adjustment on age, gender and other risk factors, with RR value as 2.07 (95%CI:1.39-3.09, P < 0.01). CONCLUSION: @entity6 @entity1 with @entity1144 seemed to have increased the risk of new-onset @entity385 events.

title: [Effect of XXXX on the events of new-onset @entity385 @entity1 ].

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['type 2 diabetes mellitus', 'Type 2 diabetes mellitus']

entities_list: @entity1144 :: ('MESH:D056128', 'Disease') :: ['central obesity']

entities_list: @entity414 :: ('MESH:D014527', 'Chemical') :: ['uric acid']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['cerebral infarction']

answer: @entity1144 :: (MESH:D056128,Disease) :: ['central obesity']


abstract: At Osaka University Hospital, the 5-year survival rate for @entity5772 , treated by radiotherapy, is almost 60% and in early cases, around 80%. However, with this improvement in the survival rate, an increase in the incidence of @entity532 ( @entity2133 , soft tissue ulcer, @entity79 , etc.) has been observed. Because of these circumstances, a radiographic analysis on the @entity79 of the mandibles after radiotherapy was made. Only those @entity1 whose progress had been followed for more than one year and whose disease was well controlled were selected for this study. Early radiographic signs of @entity79 showed an enlargement of the periodontal space and a @entity393 . From the results of the study it has been found that @entity79 is less common in @entity1 treated by interstitial radiotherapy alone. Bone damage seems to develop more frequently in @entity1 who receive about 30 Gy by external radiotherapy, followed by more than 2,000 mgh. Ra. eq. of interstitial radiotherapy.

title: [Bone damage of mandibles after radiotherapy of XXXX ].

entities_list: @entity2133 :: ('MESH:D014987', 'Disease') :: ['xerostomia']

entities_list: @entity532 :: ('MESH:D003925', 'Disease') :: ['various complications']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['bone damage', 'bone damages']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['loss of lamina dura']

entities_list: @entity5772 :: ('MESH:D014062', 'Disease') :: ['carcinoma of the tongue']

answer: @entity5772 :: (MESH:D014062,Disease) :: ['carcinoma of the tongue']


abstract: The purpose of this study was to measure serum @entity908 kinase (CK) activity and serum @entity5632 (MG) concentrations in @entity1 after two unilateral isometric knee extension exercises. Forty maximal @entity2472 (MVC) were held for 10 s, with either a 5 s (10:5) or 20 s 10:20 exercise (349.4 +/- 66.1 mU . ml-1) and 6 h and MG values were measured pre, 0, 3, 6, and 18 h post exercise. For CK, the highest post exercise values were observed at 6 h following the 10:20 exercise (349.4 +/- 66.1 mU . ml-1) and 6 h following the 10:5 exercise (194.1 +/- 18.6 mU . ml-1). For MG, the highest values were found 3 h after the 10:20 exercise (148.9 +/- 61.7 ng . ml-1) and 6 h after the 10:5 exercise (67.3 +/- 10.9 ng . ml-1). Serum CK and MG levels were significantly greater (p less than 0.01) after the 10:20 exercise bout. The data demonstrate that CK and MG values for @entity1 increase significantly after isometric exercise. Since greater @entity2701 levels were maintained during the 10:20 exercise it is hypothesized that increased serum CK and MG values after isometric exercise may be related to the @entity2701 generated by the contracting muscle.

title: Levels of serum @entity908 kinase and XXXX in @entity1 after two isometric exercise conditions.

entities_list: @entity908 :: ('MESH:D003401', 'Chemical') :: ['creatine']

entities_list: @entity2472 :: ('MESH:C536214', 'Disease') :: ['voluntary contractions']

answer: @entity5632 :: (4151,Gene) :: ['myoglobin']


abstract: AIMS: We previously generated @entity7878 -expressed recombinant porcine @entity4179 (LL-pEGF), and demonstrated improved growth performance in early-weaned piglets. This study investigates the effect of LL-pEGF on the development and expression of genes that maintain the structural integrity and function of the small intestine in early-weaned piglets. METHODS AND RESULTS: The mitogenic effect of porcine @entity4179 (pEGF) was tested in  vitro with the @entity1603 ( @entity1603 ) incorporation assay in fibroblast cells. In the in  vivo study, 40 weaned piglets were randomly allocated to control, antibiotic control, Lc.  lactis-expressing empty vector (LL-EV) and LL-pEGF treatment groups. Cells treated with LL-pEGF had higher @entity1603 -positive stained cells than those in the control and the LL-EV treatments (P  <  0  05). Scanning electron microscope and histological examination demonstrated that the small intestinal villi treated with LL-pEGF were higher (P  <  0  05) than in the other treatments. LL-pEGF increased the messenger RNA (mRNA) expression levels of the intestinal structural integrity proteins trefoil factor 3, claudin 1 (CLDN1), occludin and zonula occludens 1 (ZO-1), the digestive enzymes @entity969 , aminopeptidase A, and aminopeptidase N, and the nutrient transporters @entity1372 / @entity413 cotransporter 1 (SGLT1), @entity413 transporter 2, and peptide transporter 1 (PEPT1) as compared with the control (P  <  0  05) in the small intestine. Meanwhile, the mRNA levels of CLDN1 in the jejunum and ZO-1 in the ileum were higher in the LL-EV group than in the control group (P  <  0  05). LL-EV and the antibiotic control increased SGLT1 mRNA in the jejunum and PEPT1 mRNA in the ileum compared with the control (P  <  0  05). CONCLUSIONS: Recombinant pEGF promotes cell mitosis. Oral administration of Lc.  lactis-expressing pEGF stimulated intestinal development by upregulating the gene expression of the intestinal structural integrity proteins, the digestive enzymes and the nutrient transporters. SIGNIFICANCE AND IMPACT OF THE STUDY: The combination of @entity4179 and genetically modified micro-organisms may be used as dietary supplements to reduce intestinal stress in animals and even @entity1 .

title: Oral administration of XXXX -expressed recombinant porcine @entity4179 stimulates the development and promotes the health of small intestines in early-weaned piglets.

entities_list: @entity1603 :: ('MESH:D001973', 'Chemical') :: ['BrdU', '5-Bromodeoxyuridine']

entities_list: @entity969 :: ('MESH:D013395', 'Chemical') :: ['sucrose']

entities_list: @entity4179 :: ('1950', 'Gene') :: ['epidermal growth factor']

entities_list: @entity7878 :: ('1358', 'Species') :: ['Lactococcus lactis']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity7878 :: (1358,Species) :: ['Lactococcus lactis']


abstract: During the past 28 years, 55 @entity292 ( @entity292 ) have developed after pulmonary resections for 52 primary and 3 recurrent @entity2 at the National @entity5 Center Hospital, Tokyo. During the same period, there were 2446 pulmonary resections for primary @entity2 , the incidence of BPF being 2.1%. As an operative mode of initial resections, pneumonectomy (26 cases) was most common, followed by lobectomy (20 cases), bronchoplasty (8 cases), and stump resection for recurrence (1 case). The following predisposing risk factors for BPF development were identified: resection for locally advanced @entity2 (80.8%); residual carcinomatous tissue at the resected end of bronchus or @entity254 line (29.1%); @entity4988 , @entity6 , or @entity134 administration (20%); pre- and postoperative adjuvant therapy (49.1%). Seven cases received no treatment for BPF because of sudden deaths by massive @entity548 (5 cases), worsening @entity55 (1 case), and spontaneous recovery (1 case). Remaining 48 cases underwent treatment; tube thoracostomy only in 7 cases and surgical interventions in 41 cases, one case of which was lost during rethoracotomy due to @entity455 . Initial surgical interventions were composed of combinations of the following procedures; direct re-suture of @entity292 (16 cases); amputation of the stump and re-closure (3 cases); completion pneumonectomy (6 cases); reinforcement and wrapping of @entity292 (27 cases); thoracoplasty (29 case). Among these 40 surgical repairs, @entity292 was successfully closed in 11 cases. In 5 cases, the @entity292 closure could be achieved after subsequent surgical procedures. Direct re-suture was successful only in 4 cases. In spite of various kinds of treatment, overall prognosis was quite poor; 37 cases died of BPF-related complications (67.3% mortality).(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Bronchopleural fistulas developing after pulmonary resections for XXXX predisposing factors, management, and prognosis].

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular rupture']

entities_list: @entity4988 :: ('MESH:D034141', 'Disease') :: ['hypoalbuminemia']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['airway bleeding']

entities_list: @entity254 :: ('MESH:C563598', 'Disease') :: ['anastomosis']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancers', 'lung cancer']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity292 :: ('MESH:D005402', 'Disease') :: ['BPFs', 'bronchopleural fistulas', 'fistula']

answer: @entity2 :: (MESH:D008175,Disease) :: ['lung cancer']


abstract: A clinical and histologic review of 25 @entity1 with melanocytic lesions classified as desmoplastic malignant @entity320 is reported. All of the lesions were located in sun-exposed sites. The average age was 61.2 years (range, 38 to 83), with a median age of 56. There were 14 female and 11 male @entity1 . @entity320 is a melanocytic and fibroblastic proliferation that occurs predominantly in the head and neck area. The bland constituent cells resemble fibroblasts and are often arranged in bundles or fascicles, which may be arrayed perpendicularly to the overlying epidermis. Enlarged and/or atypical cells are usually scattered among the spindled cells. Most, but not all, of the @entity5 (24 of 25 in this series) are associated with @entity552 or an atypical junctional melanocytic proliferation. Mitotic figures are always found within the constituent cells of the fibrous-appearing mass, and neurotropism may be present. @entity1 with @entity320 typically present with a mass, which is occasionally associated with a @entity66 . The lesions in our series were deeply invasive to level IV or V. @entity552 and a dermal fibroblastic-appearing mass containing atypical cells arranged in fascicles are the most common morphologic features found in @entity320 . Follow-up data is available for 23 @entity1 . The average length of follow-up was 2.7 years (range, 0.1 to 9 years). Eighteen @entity1 were observed for 3 or more years. Twelve @entity1 developed local recurrences, and five developed @entity3 ; three of the @entity1 with @entity3 had a local recurrence before the development of @entity3 . Three of the @entity1 with @entity320 died of @entity5 between 2 and 4 years after their initial excision. Eight of the 12 locally recurring lesions were either diagnosed initially as a benign lesion or histologic examination was not performed on the initial excision specimen. It appears that recurrence may be related to inadequate initial therapy.

title: XXXX . A clinicohistopathologic study of 25 cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['pigmented lesion']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity552 :: ('MESH:D018327', 'Disease') :: ['lentigo maligna', 'Lentigo maligna']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'desmoplastic melanoma', 'metastatic melanoma', 'Desmoplastic malignant melanoma']

answer: @entity320 :: (MESH:D008545,Disease) :: ['Desmoplastic malignant melanoma']


abstract: OBJECTIVES: @entity21728 is a rare @entity3459 with worldwide distribution. In Austrian @entity1 only one mutation leading to @entity21728 has been reported. In the present study, we identified the molecular basis of @entity21728 in three Austrian @entity1 . METHODS: @entity1 attended hospital for other reasons than bleeding disorders. Routine laboratory tests revealed prolonged APTTs due to decreased factor XI levels. We performed automated fluorescent sequencing of the promotor region, exons 1-15 and the flanking intronic regions of the factor XI gene. The mutations found were confirmed by restriction enzyme analysis or sequencing of the non-coding strand. RESULTS: Fluorescent sequencing revealed two novel mutations, the nonsense mutation @entity58549 ( @entity58550 ) in exon 5 and a deletion of Ile197 and @entity2574 198 ( @entity58551 ) in exon 7. Furthermore, we detected a heterozygous @entity4866 exchange at the third nucleotide of IVS6 ( @entity58552 ), which had already been reported in a @entity6418 deficient individual of French Basque origin. CONCLUSION: While the @entity58552 decreases the calculated splice consensus score from 0.98 in the wild type to 0.56 in the altered sequence and therefore interferes with the consensus splice sequence, the complete loss of the two @entity1522 Ile197 and @entity2574 198 is expected to interfere with the steric structure and hence the functions of the third apple domain. The @entity58549 leads to a premature termination codon resulting in a lack of the light as well as parts of the heavy chain of the @entity6418 protein, most likely resulting in rapid degradation of the truncated mRNA.

title: @entity6418 gene analysis in three factor XI deficient Austrian XXXX .

entities_list: @entity21728 :: ('MESH:D005173', 'Disease') :: ['Hereditary factor XI deficiency', 'congenital factor XI deficiency', 'factor XI deficiency']

entities_list: @entity1522 :: ('CHEBI:33709', 'Chemical') :: ['amino acids']

entities_list: @entity58549 :: ('p|SUB|Q|116|X', 'ProteinMutation') :: ['Gln116X']

entities_list: @entity3459 :: ('MESH:D025861', 'Disease') :: ['bleeding disorder']

entities_list: @entity4866 :: ('c|SUB|A||G', 'DNAMutation') :: ['A>G']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: The ERM (ezrin, radixin and @entity20037 ) family members, located just beneath the plasma membranes, are thought to be involved in the association of action filaments with the plasma membrane. One of the family members, @entity20037 , is reported to bind to @entity1759 . Splice variants of @entity1759 are thought to be associated with @entity5 progression or differentiation. Our aim was to investigate immunohistochemically the expression of @entity20037 together with @entity1759 on paraffin tissue sections of a series of @entity5 . The material included 12 ordinary melanocytic naevi, six Spitz naevi, eight @entity6349 , six blue naevi, seven @entity320 in situ, 15 primary @entity320 , five metastatic @entity320 to the skin and five lymph node @entity3 . In the normal skin and the @entity5 the expression of @entity20037 was largely similar to that of @entity1759 standard. Strong @entity20037 staining was observed in benign melanocytic lesions and @entity320 in situ. However, the expression was decreased in advanced @entity320 . The @entity20037 labelling in @entity320 cells was downregulated with the depth of dermal invasion. The immunoreactivity was also diminished in the skin @entity3 and the lymph node @entity3 of @entity320 . These results suggest that in @entity5 , the alternation in the expression of @entity20037 may be involved in the progression of @entity5 .

title: XXXX and @entity1759 expression in cutaneous @entity5 .

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'malignant melanomas', 'melanomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour', 'melanocytic tumours', 'malignancy']

entities_list: @entity6349 :: ('MESH:D004416', 'Disease') :: ['dysplastic naevi']

answer: @entity20037 :: (4478,Gene) :: ['Moesin']


abstract: PURPOSE: @entity1636 ( @entity1636 ) is a rare malignancy known for high rates of local recurrence, though the benefit of postoperative @entity1161 ( @entity1161 ) has not been established. In this study of grossly resected @entity1636 , we compare local control of @entity1 treated with surgery followed by adjuvant @entity1161 to a matched cohort treated with surgery alone. METHODS AND MATERIALS: We retrospectively identified @entity1 with @entity66 who underwent R0 or R1 resection followed by adjuvant @entity1161 . Only @entity1 treated with @entity1161 at our institution were included. Matching to surgical controls was on the basis of stage, surgical margin status, @entity5 grade, and adjuvant mitotane. RESULTS: From 1991 to 2011, 360 @entity1636 @entity1 were evaluated for @entity1636 at the University of Michigan (Ann Arbor, MI). Twenty @entity1 with @entity66 received postoperative adjuvant @entity1161 . These were matched to 20 controls. There were no statistically significant differences between the groups with regard to stage, margins, grade, or @entity8449 . Median @entity1161 dose was 55  Gy (range, 45-60  Gy). Median follow-up was 34  months. Local recurrence occurred in 1 @entity1 treated with @entity1161 , compared with 12 @entity1 not treated with @entity1161 (P=.0005; hazard ratio [HR] 12.59; 95% confidence interval [CI] 1.62-97.88). However, recurrence-free survival was no different between the groups (P=.17; HR 1.52; 95% CI 0.67-3.45). Overall survival was also not significantly different (P=.13; HR 1.97; 95% CI 0.57-6.77), with 4 deaths in the @entity1161 group compared with 9 in the control group. CONCLUSIONS: Postoperative @entity1161 significantly improved local control compared with the use of surgery alone in this case-matched cohort analysis of grossly resected @entity1636 @entity1 . Although this retrospective series represents the largest study to date on adjuvant @entity1161 for @entity1636 , its findings need to be prospectively confirmed.

title: Adjuvant Radiation Therapy Improves Local Control After Surgical Resection in @entity1 With  Localized XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity8449 :: ('MESH:D008939', 'Chemical') :: ['mitotane']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['localized disease']

entities_list: @entity1161 :: ('MESH:D011832', 'Disease') :: ['radiation therapy', 'RT']

entities_list: @entity1636 :: ('MESH:D018268', 'Disease') :: ['Adrenocortical carcinoma', 'ACC']

answer: @entity1636 :: (MESH:D018268,Disease) :: ['Adrenocortical Carcinoma']


abstract: AIM: To study the role of @entity16332 in improving the efficiency of interferon for the treatment of @entity6194 . METHODS: Fifteen @entity1 with @entity6194 were prospectively studied. All @entity1 had liver histology and serology to prove the diagnosis of @entity6194 . Each @entity1 received 4.5 million units of @entity4020 thrice weekly and 100 mg of oral @entity16332 daily for 24 weeks. @entity1 were observed and tested for blood chemistry every week for the initial 4 weeks and every 2 weeks thereafter during the treatment until 24 weeks. After the end of treatment, @entity1 were followed up at 4-week intervals for an additional 6 months. Serum HBV DNA levels were tested using the liquid phase molecular hybridization assay. Those with non-detectable @entity97 DNA were also tested using the real-time polymerase chain reaction. One @entity1 , who did not finish treatment due to @entity308 , was excluded. RESULTS: At the end of treatment, 7 (50 %) patients had serum ALT levels within normal limits; 12 (86 %) patients had serum HBV DNA levels <5 pg/mL using the liquid phase molecular hybridization assay, but only 8 (67%) were <20 copies/dL using the real-time polymerase chain reaction. Six months after treatment, only two (14 %) @entity1 had a sustained complete response to the combination therapy with serum ALT level <35 iu/L and undetectable serum HBV DNA levels. CONCLUSION: These pilot data showed that @entity16332 did not increase the efficacy of interferon in the treatment of @entity6194 . The liquid phase molecular hybridization assay was not sensitive enough to detect the low @entity97 DNA levels during combined interferon and @entity16332 therapy.

title: @entity16332 does not increase the efficacy of interferon in the treatment of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity16332 :: ('MESH:D019259', 'Chemical') :: ['lamivudine']

entities_list: @entity6194 :: ('MESH:D019694', 'Disease') :: ['chronic hepatitis B', 'mutant type chronic hepatitis B']

entities_list: @entity4020 :: ('3440', 'Gene') :: ['interferon alpha-2a']

answer: @entity6194 :: (MESH:D019694,Disease) :: ['mutant type chronic viral hepatitis B']


abstract: BACKGROUND: Although pulmonary function is minimally changed by neuraxial blockade in most cases, @entity1167 may ensue in rare cases. The authors examined the mechanism of @entity386 in a @entity95 model of @entity1164 during the combination of epidural anesthesia and @entity519 . METHODS: @entity95 were studied during alpha-chloralose sedation and spontaneous ventilation through a tracheostomy tube. Heart rate and mean arterial pressure were monitored by intraarterial cannulation. Respiratory rate and tidal volume were measured by pneumotachograph. Responses were recorded during administration of @entity26 at inspired @entity26 concentrations of 11% for 2.5 min and 0% for 40 s, before and after either thoracolumbar epidural blockade (0.4 ml/kg @entity3303 , 1.5%) or intramuscular @entity3303 (15 mg/kg). In a third group of animals, @entity1425 was given intravenously during epidural blockade to return mean arterial pressure to baseline values before @entity519 . In a fourth group of animals, which did not get @entity3303 , sympathetic blockade and @entity551 were produced with intravenously administered @entity13673 rather than epidural blockade. RESULTS: Thoracolumbar epidural anesthesia decreased mean arterial pressure from 76 +/- 4 mmHg (mean +/- SE) to 42 +/- 2 mmHg. @entity386 during @entity519 occurred in 90% of these animals (nine of ten) but in only 11% of animals (one of nine) after intramuscularly administered @entity3303 (P < 0.01). Treatment of @entity551 with @entity1425 prevented @entity386 (zero of nine animals). @entity386 during @entity519 occurred in 50% (three of six) of animals given @entity13673 . @entity386 in all groups was sudden in onset, with no preceding decreases in respiratory rate or tidal volume. CONCLUSIONS: Epidural anesthesia results in a narrowed margin of safety for @entity26 delivery to the brain and predisposes subjects to @entity1167 during @entity519 . This results from the combined effects of decreased blood @entity26 content, which is due to decreased inspired @entity26 concentration superimposed on @entity308 due to neural blockade.

title: @entity519 causes @entity386 during epidural anesthesia in XXXX .

entities_list: @entity1164 :: ('MESH:D016757', 'Disease') :: ['sudden ventilatory arrest']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['circulatory depression']

entities_list: @entity1425 :: ('MESH:D004837', 'Chemical') :: ['epinephrine']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity95 :: ('9986', 'Species') :: ['Rabbits', 'rabbit']

entities_list: @entity3303 :: ('MESH:D008012', 'Chemical') :: ['lidocaine']

entities_list: @entity13673 :: ('MESH:D014294', 'Chemical') :: ['trimethaphan']

entities_list: @entity1167 :: ('MESH:D006323', 'Disease') :: ['ventilatory arrest']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['epidural hypotension', 'hypotension']

answer: @entity95 :: (9986,Species) :: ['rabbits']


abstract: PURPOSE: Treatment of long-gap esophageal @entity1146 challenges pediatric surgeons. Dr. Foker described utilization of external traction sutures to promote in-vivo growth through @entity2701 -induced lengthening, but reproducibility of this technique is difficult. We describe a safe and reproducible traction system using transduction of hydrostatic pressure as a surrogate for @entity2701 . METHODS: We conducted a multi-institutional review of @entity1 treated with this system from 2005 to 2012. All @entity1 had sutures applied to both pouches with continuous measurement of associated hydrostatic pressures ( @entity2701 ). Main outcome measures were days to delayed primary repair and thoracotomies prior to primary repair. RESULTS: Seven @entity1 were included. Median time to delayed repair was 15 days (range: 6-47 days). Three @entity1 required repeat thoracotomies owing to mechanical entrapment of a pouch, all identified early by this system. All required postoperative dilations. Three had self-limited postdilation leaks, and there was one operation-related leak. CONCLUSIONS: This system provides reproducible traction application, facilitating staged primary repair by preventing major failures through limiting excessive traction and guides re-exploration for trapped segments. Larger studies are needed to determine the optimal @entity2701 protocol, prevent postoperative leaks, while decreasing the need for dilations and time to enteral feeding.

title: Early results of an objective feedback-directed system for the staged traction repair of long-gap esophageal XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'children']

answer: @entity1146 :: (MESH:D018633,Disease) :: ['atresia']


abstract: BACKGROUND/AIMS: Gelatinase ( @entity5379 ) has an important role in the pathogenesis of @entity1575 ( @entity1575 ) and @entity157 ( @entity157 ). In this study, we evaluated the relationship of gelatinase to @entity409 . METHODS: Four groups of subjects were examined; healthy control (10 cases), @entity3619 (18 cases), @entity1575 (15 cases), and @entity157 (28 cases). The plasma of each subject was obtained, and the equal quantification of plasma protein was done. The plasma activities of @entity1476 and 9 were measured by zymography. RESULTS: The activities of plasma @entity1476 in @entity1 with @entity1575 were significantly higher than those in controls (p=0.009) and in @entity1 with @entity3619 (p=0.011), but not different from those in @entity1 with @entity157 . The activities of plasma @entity1495 in @entity1 with @entity1575 were significantly higher than those in controls, but not different from those in @entity1 with @entity3619 or @entity157 . In @entity1 with @entity1575 (regardless of having @entity157 ), the activities of @entity1476 correlated with total @entity648 (r=0.323, p=0.048) and @entity1 -Pugh score (r=0.414, p=0.012). The activities of @entity1476 and 9 were higher in @entity1 with @entity1575 (regardless of having @entity157 ) caused by @entity167 than caused by @entity97 (p=0.009 and 0.002 for each one). CONCLUSIONS: The plasma activity of @entity1476 may be a useful marker for the diagnosis and determination of the severity of @entity1575 . The plasma activity of @entity1495 was not useful for @entity157 , but may be a marker for alcoholic @entity1575 . Further study is needed to determine why the plasma activity of gelatinase was higher in @entity1 with @entity1575 caused by @entity167 than by @entity97 .

title: [Clinical usefulness of plasma activities of gelatinase ( @entity5379 ) in XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['Child', 'patients']

entities_list: @entity5379 :: ('4313;4318', 'Gene') :: ['matrix metalloproteinase (MMP) -2 and 9']

entities_list: @entity167 :: ('CHEBI:16236', 'Chemical') :: ['alcohol']

entities_list: @entity648 :: ('MESH:D001663', 'Chemical') :: ['bilirubin']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['chronic liver disease']

entities_list: @entity3619 :: ('MESH:D006521', 'Disease') :: ['chronic hepatitis']

entities_list: @entity1575 :: ('MESH:D008103', 'Disease') :: ['LC', 'liver cirrhosis']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma']

answer: @entity409 :: (MESH:D008107,Disease) :: ['chronic liver disease']


abstract: @entity2983 ( @entity3504 ) is an agent widely used in the treatment of @entity29 . @entity3504 has been shown to be a potential scavenger of the oxidants, such as @entity9784 ( @entity9785 ), that are released by neutrophils present in @entity29 . We studied the oxidation of @entity3504 by @entity9785 and characterized the reaction pathway involving reactive intermediates. The reactive intermediates in the reaction of @entity3504 with @entity9785 were identified by use of a flow system interfaced with a Sciex API III mass spectrometer. The mass spectral analysis revealed the formation of @entity62431 and @entity3276 reactive intermediates. The major stable product formed was identified as @entity22559 . The @entity62431 and @entity3276 intermediates were trapped by @entity2041 ( @entity2197 ) and the products analyzed by LC/MS. The major conjugate was formed from the @entity3276 with one dominant isomer. In contrast, three isomers of the @entity62431 - @entity2197 conjugates were observed in almost equal proportion. Covalent binding of the reactive intermediates to the @entity7722 of @entity1 hemoglobin was also observed. We propose that the @entity62431 is the major intermediate formed in the scavenging of neutrophil-generated @entity9785 by @entity3504 . Although this reaction may inactivate @entity9785 and be responsible for the antiinflammatory effects of the drug, it also forms reactive intermediates that covalently bind to protein and may be responsible for adverse reactions that are associated with the use of the drug.

title: Oxidation of @entity2983 by @entity9784 to a reactive @entity62431 . Possible role in the treatment of XXXX .

entities_list: @entity9784 :: ('MESH:D006997', 'Chemical') :: ['hypochlorous acid']

entities_list: @entity22559 :: ('MESH:C010925', 'Chemical') :: ['gentisic acid']

entities_list: @entity62431 :: ('MESH:C116897', 'Chemical') :: ['iminoquinone']

entities_list: @entity2041 :: ('MESH:D005978', 'Chemical') :: ['glutathione']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease']

entities_list: @entity2983 :: ('MESH:D019804', 'Chemical') :: ['5-Aminosalicylic acid']

answer: @entity29 :: (MESH:D015212,Disease) :: ['inflammatory bowel diseases']


abstract: UNASSIGNED: Studies have suggested a compromised postural control in individuals with @entity626 ( @entity571 ) evidenced by larger and faster displacement of center of pressure (COP). However, quantification of postural control in the mini-squat posture performed by @entity1 with early knee @entity571 and its relation to muscle strength and self-reported symptoms have not been investigated. The main aim of this cross-sectional, observational, controlled study was to determine whether postural control in the mini-squat posture differs between individuals with early knee @entity571 and a control group (CG) and verify the relation among knee extensor torque (KET) and self-reported physical function, stiffness and @entity158 . Twenty four individuals with knee @entity571 grades I and II (OAG) (mean age: 52.35  5.00) and twenty subjects without @entity3331 (CG) (mean age: 51.40  8.07) participated in this study. @entity1 were assessed in postural control through a force plate (Bertec Mod. USA), which provided information about the anterior-posterior (AP) and medial-lateral (ML) COP displacement during the mini-squat, in isometric, concentric and eccentric knee extensor torque (KET) (90  /s) through an isokinetic dynamometer (BiodexMulti-Joint System3, Biodex Medical Incorporation, New York, NY, USA), and in self-reported symptoms through the WOMAC questionnaire. The main outcomes measured were the AP and ML COP amplitude and velocity of displacement; isometric, concentric, and eccentric KET and self-reported physical function, stiffness and @entity158 . No significant differences were found between groups for postural control (p>0.05). Significant lower eccentric KET (p=0.01) and higher scores for the WOMAC subscales of @entity158 (p=<0.001), stiffness (p=0.001) and physical function (p<0.001) were found for the OAG. Moderate and negative correlations were found between the AP COP amplitude of displacement and physical function (  =-0.40, p=0.02). Moderate and negative correlations were observed between the AP COP velocity of displacement and physical function (  =0.47, p=0.01) and stiffness (  =-0.45, p=0.02). The findings of the present study emphasize the importance of rehabilitation from the early degrees of knee @entity571 to prevent postural instability and the need to include @entity121 strengthening, especially by eccentric contractions. The relationship between the self-reported symptoms and a lower and @entity551 suggest that the postural control strategy during tasks with a semi-flexed knee should be further investigated.

title: Measuring postural control during mini-squat posture in @entity1 with early XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Participants']

entities_list: @entity626 :: ('MESH:D020370', 'Disease') :: ['knee osteoarthritis']

entities_list: @entity3331 :: ('MESH:D007718', 'Disease') :: ['knee injuries']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['slower COP displacement']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['quadriceps muscle']

answer: @entity626 :: (MESH:D020370,Disease) :: ['knee osteoarthritis']


abstract: BACKGROUND AND AIMS: Limited data are available regarding fully covered metal stents in the management of @entity5 . The aim of this study was to evaluate the safety of a fully covered self-expanding metal stent (FCSEMS) with flared ends, in treating @entity5 . We report our long-term retrospective analysis from 6 centers. METHODS: A total of 260 @entity1 (142 males, median age 68 y) underwent endoscopic retrograde cholangiopancreatography with placement of FCSEMS (WallFlex; Boston Scientific, Natick, MA) for the @entity3883 in the setting of @entity788 (169), @entity3 (36), @entity201 (23), @entity5 (19), or other (13). @entity1 were evaluated clinically in follow-up and biochemical tests of liver function were obtained. Data were recorded for the following variables: @entity1 survival, duration of stent patency, the need for subsequent biliary intervention, and complications. RESULTS: A total of 266 FCSEMS were placed in 260 @entity1 . There was a median survival of 100 days (range, 7 to 531 d). There was a mean follow-up of 134  118 days (range, 4 to 519 d). Biliary decompression was successful in 252 @entity1 (97%). At the end of the study period, 121 were alive with a patent stent, 65 @entity1 died with a patent stent, 40 @entity1 were successfully bridged to surgery, 8 @entity1 had their patent stent removed and had no need for further stenting, and 18 @entity1 were lost to follow-up. Five @entity1 who had a successfully placed FCSEMS were considered a failure due to the following reason: @entity4222 (2), @entity255 (1), stent occlusion (1), and removal for management of proximal @entity253 (1). Two additional @entity1 experienced @entity4222 that did not require FCSEMS removal or replacement. Stent replacement was required in 10 @entity1 , of whom 6 had a second FCSEMS placed. The remaining 4 were in the failure group and underwent replacement with either uncovered stents or plastic stents. Other complications, managed conservatively, included @entity158 (2), postendoscopic retrograde cholangiopancreatography @entity788 (4), fever (1), retroperitoneal perforation (1), and @entity548 (1). The mean patency duration was 328 days (SE 19.04). The patency percentage was 83% at 3 months, 63% at 6 months, and 48.5% at 12 months. CONCLUSIONS: In the management of @entity5 , the fully covered WallFlex stent has acceptable patency and complication rates. Further long-term prospective data are required to confirm this observation.

title: Evaluation of a fully covered self-expanding metal stent with flared ends in XXXX : a multicenter study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity3883 :: ('MESH:D041781', 'Disease') :: ['palliation of obstructive jaundice']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis', 'pancreatic adenocarcinoma']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['postsphincterotomy bleeding']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['ampullary cancer', 'malignant biliary strictures', 'malignant distal biliary strictures']

entities_list: @entity4222 :: ('MESH:D014085', 'Disease') :: ['migration']

entities_list: @entity201 :: ('MESH:D018281', 'Disease') :: ['cholangiocarcinoma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease']

entities_list: @entity253 :: ('MESH:D001660', 'Disease') :: ['biliary obstruction']

entities_list: @entity255 :: ('MESH:D002761', 'Disease') :: ['cholangitis']

answer: @entity5 :: (MESH:D009369,Disease) :: ['malignant biliary obstruction']


abstract: Tendon healing is a complex process consisting of a large number of intricate pathways roughly divided into the phases of @entity32 , proliferation, and remodeling. Although these processes have been extensively studied at a variety of levels in recent years, there is still much that remains unknown. This study used microarray analyses to investigate the process at a genetic level in healing @entity35 Achilles tendon at 1, 7, and 21 days postinjury, roughly representing the @entity32 , proliferation, and remodeling phases. An interesting temporal expression profile was demonstrated, identifying both known and novel genes and pathways involved in the progression of @entity924 . Both inflammatory response and pro-proliferative genes were shown to be significantly upregulated from 24 h postinjury through to 21 days. Day 7 showed the largest increase in genetic activity, particularly with the expression of collagens and other extracellular matrix genes. Interestingly, there was also evidence of central nervous system-like @entity2227 -based signaling machinery present in tendon cells, as has recently been shown in bone. This type of signaling mechanism has not previously been shown to exist in tendon. Another novel finding from these analyses is that there appears to be several genes upregulated during healing which have exclusively or primarily been characterized as key modulators of proliferation and patterning during embryonic development. This may suggest that similar pathways are employed in wound healing as in the tightly regulated progression of growth and development in the embryo. These results could be of use in designing novel gene-based therapies to increase the efficacy and efficiency of @entity924 .

title: Microarray analysis of healing XXXX Achilles tendon: evidence for @entity2227 signaling mechanisms and embryonic gene expression in healing tendon tissue.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity924 :: ('MESH:D052256', 'Disease') :: ['tendon healing']

entities_list: @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate']

answer: @entity35 :: (10116,Species) :: ['rat']